Composition for preventing or treating renal diseases, comprising exosomes derived from precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells
AssigneeBrexogen Inc.
InventorsSue Kim, Seul Ki Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition for preventing or treating renal diseases, comprising, as an active ingredient, exosomes isolated from precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells, the precursor cells having been treated or not having been treated with a pretreatment material. Exosomes of the present invention exhibit an effect of preventing or treating renal diseases that is more improved than that of exosomes isolated from conventional mesenchymal stem cells, thereby being effectively usable for relevant research and development and productization.
Claims7
An exosome, isolated from pretreatment material-pretreated progenitor cells of induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs),
- wherein the progenitor cell of induced pluripotent stem cell-derived mesenchymal stem cell is pretreated for 12 to 36 hours, and
- wherein the pretreatment material is 10 to 100 nM of exendin-4 or 5 to 50 μM of lanifibranor.
A method for treating a kidney disease in a subject in need thereof, the method comprising:
- administering to the subject a composition comprising exosomes isolated from progenitor cells of induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (MSC),
- wherein the progenitor cell of induced pluripotent stem cell-derived mesenchymal stem cell is pretreated for 12 to 36 hours, and
- wherein the pretreatment material is 10 to 100 nM of exendin-4 or 5 to 50 μM of lanifibranor.
A method for preventing or treating a kidney disease in a subject in need thereof, the method comprising:
- administering to the subject a composition comprising exosomes isolated from induced pluripotent stem cell (iPSC)-derived mesenchymal stem cell (MSC) progenitor cells treated with a pretreatment material,
- wherein the progenitor cell of induced pluripotent stem cell-derived mesenchymal stem cell is pretreated for 12 to 36 hours, and
- wherein the pretreatment material is 10 to 100 nM of exendin-4 or 5 to 50 μM of lanifibranor.
Dependencies are inferred from the claim text.